Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Granules India Limited ( (IN:GRANULES) ) just unveiled an update.
Granules India Limited’s board has approved a significant capital-raising plan comprising the issuance of up to 25 million convertible warrants at Rs 585 each, aggregating to Rs 1,462.50 crore, on a preferential basis to promoter group and non-promoter investors. In addition, the board cleared a preferential issue of up to 5.13 million fully paid equity shares at Rs 585 per share, raising up to Rs 300 crore from non-promoter investors, with both issuances subject to shareholder and regulatory approvals at an extraordinary general meeting scheduled for January 22, 2026, to be held via video conferencing. The combined fundraising, if completed, will substantially bolster the company’s equity base and financial flexibility, potentially supporting future growth initiatives and strengthening its position in the competitive pharmaceutical sector.
More about Granules India Limited
Granules India Limited is an India-based pharmaceutical company engaged in manufacturing and supplying active pharmaceutical ingredients and finished dosage forms. The company operates in the global generics and pharmaceutical ingredients market, serving both domestic and international customers from its facilities in Hyderabad, Telangana.
Average Trading Volume: 41,040
Technical Sentiment Signal: Strong Buy
Current Market Cap: 141.5B INR
Find detailed analytics on GRANULES stock on TipRanks’ Stock Analysis page.